Tempest Therapeutics, Inc.
TPST•NASDAQ•Healthcare•Biotechnology

About Tempest Therapeutics

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOStephen Brady
Founded2011
Employees24
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.tempesttx.com
Phone415 798 8589
Address
2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 United States

Corporate Identifiers

CIK0001544227
CUSIP87978U207
ISINUS87978U2078
EIN45-1472564
SIC2834

Leadership Team & Key Executives

Stephen R. Brady J.D., LLM
Chief Executive Officer, President and Director
Nicholas Maestas
Chief Financial Officer, Head of Corporate Strategy and Secretary
Dr. Samuel Whiting M.D., Ph.D.
Executive Vice President, Chief Medical Officer and Head of Research & Development
Justin Trojanowski CPA
Corporate Controller, Treasurer and Principal Accounting Officer